Targets › ICAM1
1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Dec 2026.
Cell adhesion molecule that functions as a receptor ligand of the signaling receptor ITGAL:ITGB2/LFA-1 (lymphocyte-function associated (LFA) molecule 1) ensuring leukocyte cell-cell adhesion, by providing a calibrated system to namely adjust T-cell killing to the antigen stimulation strength. Also functions as a ligand receptor of the signaling receptor ITGAM:ITGB2/MAC-1 ensuring adhesion between stimulated…. (UniProt, P05362)
Open in Phaseline: the race on ICAM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Oculis | licaminlimab Anti-ICAM-1 antibody | ICAM1 | Phase 2 | Dry Eye Disease (DED) | Dec 2026 |
Dry Eye Disease (DED) (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.